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Dipeptidyl Peptidase-4 Is a Pro-Recovery 
Mediator During Acute Hepatotoxic 
Damage and Mirrors Severe Shifts in 
Kupffer Cells
nádia Duarte,1 inês Coelho,1 Denys Holovanchuk,1,2 Joana inês almeida,1 Carlos penha-gonçalves,1,3* and  
maria paula macedo,2-4*
Dipeptidyl peptidase-4 (DPP-4 or clusters of differentiation [CD]26) is a multifunctional molecule with established roles in 
metabolism. Pharmacologic inhibition of DPP-4 is widely used to improve glycemic control through regulation of the incre-
tin effect. Colaterally, CD26/DPP-4 inhibition appears to be beneficial in many inf lammatory conditions, namely in delay-
ing progression of liver pathology. Nevertheless, the exact implications of CD26/DPP-4 enzymatic activity in liver 
dysfunction remain unclear. In this work, we investigated the involvement of CD26/DPP-4 in experimental mouse models 
of induced hepatocyte damage that severely impact Kupffer cell (KC) populations. Liver dysfunction was evaluated in CD26 
knockout (KO) and B6 wild-type mice during acute liver damage induced by acetaminophen, chronic liver damage induced 
by carbon tetrachloride, and KC-depleting treatment with clodronate-loaded liposomes. We found that necrosis resolution 
after hepatotoxic injury was delayed in CD26KO mice and in B6 mice treated with the CD26/DPP-4 inhibitor sitagliptin, 
suggesting that DPP-4 enzymatic activity plays a role in recovering from acute liver damage. Interestingly, the severe KC 
population reduction in acute and chronic liver injury was concomitant with increased CD26/DPP-4 serum levels. 
Remarkably, both chronic liver damage and noninf lammatory depletion of KCs by clodronate liposomes were marked by 
oscillation in CD26/DPP-4 serum activity that mirrored the kinetics of liver KC depletion/recovery. Conclusion: CD26/
DPP-4 enzymatic activity contributes to necrosis resolution during recovery from acute liver injury. Serum CD26/DPP-4 is 
elevated when severe perturbations are imposed on KC populations, regardless of patent liver damage. We propose that 
serum CD26/DPP-4 is a potential systemic surrogate marker of severe impairments in the KC population imposed by clini-
cal and subclinical liver conditions. (Hepatology Communications 2018;2:1080-1094)
Clusters of differentiation (CD)26, also known as dipeptidyl peptidase-4 (DPP-4), occurs as a transmembrane glycoprotein of 110 kDa 
in many cell types or in soluble form in most body 
fluids. It has been shown to cleave two N-terminal 
amino acids in small polypeptides, usually with pro-
line or alanine in the second position.(1,2) Inactivation 
of incretin gastrointestinal hormones glucagon-like 
polypeptide 1 and glucose-dependent insulinotropic 
polypeptide is currently the most clinically relevant 
function attributed to this enzyme.(3) Glucagon-like 
polypeptide 1 and glucose-dependent insulinotropic 
polypeptide cleaved by CD26/DPP-4 are rapidly tar-
geted for degradation, and pharmacologic inhibition 
of DPP-4 activity is a prime strategy in the treatment 
of type 2 diabetes as it prolongs the incretin effect. 
Nevertheless, CD26/DPP-4 is multifunctional, act-
ing on many substrates, including chemokines, and 
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binding to various other molecules, such as adenosine 
deaminase.(4‒6) Accordingly, multiple nonglycemic 
effects of CD26/DPP-4 inhibition therapy have been 
reported.(7) Interestingly, a beneficial impact in atten-
uation of inflammation and an increased susceptibility 
to infections have been noted.(5) Additionally, circu-
lating DPP-4 concentrations are increased in various 
inflammatory diseases, highlighting the relevance of 
CD26/DPP-4 in immune activation.(8)
The proteolytic activity of DDP-4 is executed 
by the extracellular portion of the molecule and is 
retained in the soluble form.(8,9) The mechanisms reg-
ulating CD26/DPP-4 secretion and release from the 
cell membrane include a metalloprotease activity that 
mediates the shedding of CD26/DPP-4 from human 
vascular smooth muscle cells and adipocytes.(10) A 
recent study using mouse genetic models has shown 
that bone marrow-derived cells and vascular endo-
thelial cells are major contributors to serum CD26/
DPP-4 levels.(11) Another study proposed the liver as 
an important source of circulating CD26/DPP-4 and 
pointed to a weight-dependent regulation of hepatic 
Dpp4 expression.(12)
CD26/DPP-4 is highly expressed in the liver, namely 
in the hepatocyte canalicular membrane facing the bile 
canaliculus, in biliary epithelial cells, and in endothelial 
cells.(13) Expression in liver macrophages was reported 
on lysosomes and at a lower level in the plasma mem-
brane.(13) Kupffer cells (KCs) are critical players in 
maintaining liver homeostasis and responsiveness to 
liver insults,(14) triggering both local responses and 
recruiting hematopoietic cells that participate in liver 
inflammatory and tissue repair responses.(15)
Protection from liver steatosis and slower progres-
sion of nonalcoholic fatty liver disease was reported 
with CD26/DPP-4 inhibitor therapy.(16) However, 
two recent randomized, placebo-controlled, clinical 
trials have failed to observe an effect of CD26/DPP-4 
enzymatic inhibition on hepatic steatosis,(17,18) and its 
impact in the development of liver pathology remains 
unsettled. This is particularly relevant in light of liver 
pathology as a common comorbidity in type 2 diabetic 
patients, increasing the risk of progression toward liver 
fibrosis and limiting the therapeutic options avail-
able for glycemic control.(19) Studies have suggested 
a potential beneficial role for DPP-4 inhibition in 
rodent models of liver fibrosis, but the pathogenic 
mechanisms proposed diverge.(20,21) Furthermore, 
the role of CD26/DPP-4 in inflammatory and tissue 
recovery phases of disease when macrophage popula-
tions are most dynamically changed has thus far been 
overlooked.
In this study, we analyzed mouse models with various 
degrees of hepatic disturbances to determine whether 
alterations in liver macrophage populations correlated 
with CD26/DPP-4 expression and enzymatic activ-
ity. Our findings suggest that CD26/DPP-4 activity 
participates in the liver recovery response to acute 
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hepatotoxic injury and is an indicator of severe shifts 
in liver macrophage populations.
Materials and Methods
miCe anD eXperimental 
moDels
All procedures involving laboratory mice were 
in accordance with national (Portaria 1005/92) and 
European (European Directive 86/609/CEE) regula-
tions on animal experimentation and were approved by 
the Instituto Gulbenkian de Ciência Ethics Committee 
and the Direcção-Geral de Veterinária (the official 
national entity for regulation of laboratory animal 
usage). C57BL/6-DPP-4tm1Nwa/Orl (CD26 knock-
out [KO]) mice were purchased from the European 
Mouse Mutant Archive (Infrafrontier Gmbh, Munich, 
Germany). C57BL/6 mice and CD26KO mice were 
bred and housed under a 12-hour light/dark cycle in 
specific pathogen-free housing facilities at the Instituto 
Gulbenkian de Ciência. In the Instituto Gulbenkian 
de Ciência mouse facility, the recommendations of the 
Federation of European Laboratory Animal Science 
Associations are followed for health screening of the ani-
mals, which includes four screenings per year (one spe-
cific and opportunistic pathogen-free annual panel and 
three specific and opportunistic pathogen-free quarter 
panels). Every animal room has one sentinel cage per 
rack; these are exposed to materials soiled by resident 
animals, such as bedding, water, and chewed food. In 
each health screening, samples from the sentinel animals 
plus random animals from the same rack are collected 
and analyzed by an outsourcing laboratory. These sam-
ples include blood, feces, and pelt swabs and are screened 
for serology, bacteria, virus, and parasites. Mice are fed 
with standard chow (Diet:RM3-A-P; Special Diets 
Services, Essex, United Kingdom (https://www.sdsdi-
ets.com/pdfs/RM3-A-P.pdf ), and water is purified by 
reverse osmosis filtering with ultraviolet treatment.
To induce acute liver injury, 10-week-old C57BL/6 
and CD26KO male mice were fasted for 15 hours 
prior to intraperitoneal injection with 300 mg/kg of 
acetaminophen (N-acetyl-p-aminophenol [APAP]) 
(Sigma, St. Louis, MO) in phosphate-buffered saline 
(PBS) or PBS only (control group). Liver and blood 
were collected 24 hours and 72 hours after injection. To 
inhibit CD26 activity, 100 mg/kg of sitagliptin (Santa 
Cruz Biotechnology, Dallas, TX) dissolved in water or 
water only was administered by daily gavage starting 3 
days prior to APAP injection and continuing until 24 
hours before organ collection at 24 hours or 72 hours. In 
the chronic liver injury model, 7-8-week-old C57BL/6 
male mice received PBS or 20% volume/volume CCl4 
(Sigma) in olive oil, administered at 0.4 mL/kg twice 
a week for 4 weeks by intraperitoneal injections. After 
this period, a final injection was given and liver and 
blood were collected 24 hours, 72 hours, or 144 hours 
postinjection. For the hypercaloric regimen experi-
ments, C57BL/6 female mice 5-6 weeks of age were 
maintained on regular chow (chow-RM3-A-P; Special 
Diets Services) or on a hypercaloric diet (HCD; cata-
log #TD.88137; Harlan, Indianapolis, IN) with 42% 
kcal fat (61.8% from saturated fatty acids) and 42.7% 
kcal carbohydrates (63% from sugar) for 6 weeks, with 
free access to food and water. Mice were weighed 
weekly, food and water intake were monitored, and 
blood and liver were collected after the experimental 
period. For KC-depletion experiments, 10-20-week-
old C57BL/6 male mice received a 200-μL injection 
of liposomes containing either PBS (used as the con-
trol group) or 5 g/mL of clodronate (depletion group) 
in the orbital plexus. Liposome preparations were pur-
chased from ClodronateLiposomes.org (Haarlem, the 
Netherlands) and used according to the manufacturer’s 
specifications. Liver and blood were collected 2, 7, 14, 
or 30 days after injection. A minimum of two indepen-
dent experiments was performed, and each experimen-
tal group ranged from three to nine mice, as specified 
in figure legends.
isolation oF Cells
Nonparenchymal cells (NPCs) were isolated from 
liver lobes by perfusion with collagenase H (Sigma) 
and density centrifugation as described.(22) To enrich 
for KCs, NPCs were placed on top of four layers of 
a Percoll (GE Healthcare, Little Chalfon, United 
Kingdom) gradient of 80%, 60%, 40%, and 20% Percoll 
and centrifuged for 20 minutes at 400g. The interface 
between the 60% and 40% Percoll layer containing the 
KCs was collected. To sort purify KCs, the enriched 
fraction was resuspended in PBS with 2% fetal calf 
serum (Life Technologies, Carlsbad, CA). Cells were 
sorted according to morphology and autofluorescence 
in the fluoroscein channel on the high-speed cell sort-
ing MoFlo (Dako-Cytomation, Berkeley, CA) after it 
was determined that the autofluorescent population 
corresponded to F4/80+ cells. Purity was controlled by 
staining with antibodies against Mac1 (clone M1/70) 
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and F4/80 (clone BM8) (both from BioLegend, San 
Diego, CA) and was higher than 90%.
Cell Culture anD IN VITRO 
stimulation
Sort-purified KCs from pools of eight C57BL/6 
and eight CD26KO sex and age-matched mice were 
cultured in complete medium (Roswell Park Memorial 
Institute medium supplemented with 2% fetal calf 
serum, 10 mM 4-(2-hydroxyethyl)-1-piperazine eth-
anesulfonic acid, 1 mM sodium pyruvate, 50 μM 
2-mercaptoethanol, 100 U penicillin, and 100 mg/mL 
streptomycin; Life Technologies) in triplicate (80,000/
well) in 96-well plates; after overnight incubation, 
these cultures were stimulated with 1 μg/mL puri-
fied lipopolysaccharide (LPS; Invitrogen, San Diego, 
CA). Supernatants were collected after 24 hours of 
stimulation for analysis of CD26/DPP-4 enzymatic 
activity and production of tumor necrosis factor alpha 
(TNF-α) and interleukin-6 (IL-6). TNF-α and IL-6 
concentrations were determined with mouse TNF-α 
enzyme-linked immunosorbent assay Ready-SET-Go 
kit (eBiosciences, San Diego, CA) and mouse IL-6 
enzyme-linked immunosorbent assay Ready-SET-Go 
kit (eBiosciences), according to the manufacturers’ 
specifications. For analysis of enzymatic inhibition, cells 
were plated in triplicate (80,000 cells/well) in 96-well 
plates and were stimulated for 24 hours with LPS 1 μg/
mL alone, sitagliptin at 10 μM, or sitagliptin at 100 μM 
alone or in combination with LPS. To examine in vitro 
induction of cell death, sorted cells were cultured for 24 
hours with clodronate-containing liposomes (5 g/mL) 
diluted 1/10 or 1/100 in culture medium. Viability 
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT) assay 
(Invitrogen). In brief, after 24 hours culture with or 
without clodronate-containing liposomes, the super-
natant was collected and cells were cultured for 1 hour 
with 0.5 mg/mL of MTT in PBS. The supernatant 
was removed, and dimethyl sulfoxide was added to 
cells to dissolve the formazan formed in viable cells. 
Absorbance was measured at 560 nm.
CD26/Dpp-4 enZymatiC 
aCtiVity
Supernatant from macrophage cultures or serum from 
total blood was measured for CD26/DPP-4 activity 
using a fluorometric assay with 200 μM of the substrate 
H-Gly-Pro-AMC HBr (#I-1225; Bachem, Bubendorf, 
Switzerland). Measurements at excitation/emission 
360/460 nm were taken every 5 minutes over the course 
of 1 hour, and the rate of change of fluorescence was 
used as a measure of cleaved substrate by CD26/DPP-4.
FloW Cytometry
Single-cell suspensions from peripheral blood or 
liver NPCs were stained according to standard pro-
cedures. Nonspecific binding to FcγIII, FcγII, and 
FcγI receptors was prevented by incubating the cells 
with unlabeled anti-mouse-Fc-block/CD16/32 (clone 
2.4G2; BD, Franklin Lakes, NJ). Liver KCs were iden-
tified using allophycocyanin-labeled anti-mouse F4/80 
antibody (clone BM8) and fluoroscein or brilliant 
violet 785-labeled anti-mouse-CD11b/Mac-1 (clone 
M1/70) (both from BioLegend). Phycoerythrin- and 
fluoroscein-labeled anti-mouse CD26 antibody (clone 
H194-112; BioLegend), efluor450-labeled anti-mouse 
Ly6c (clone HK1.4; eBiosciences), and allophyco-
cyanin- or phycoerythrin-labeled anti-mouse CD45 
(clone 30-F11; BioLegend) were further used to char-
acterize mouse liver macrophages and blood monocytes. 
Traceable latex beads (Polysciences, Warrington, PA) 
were added for counting cells. Stained cell suspensions 
were analyzed by flow cytometry (LSR Fortessa X20 
[BD] or CyAn ADP [Beckman Coulter]), and the data 
acquired with DIVA software (BD). Analysis was per-
formed with FlowJo software (TreeStar, Ashland, OR).
Histology
Livers were fixed in 10% formalin and embedded in 
paraffin. Nonconsecutive 3-µm sections were stained 
with hematoxylin-eosin or Mason’s trichrome and 
examined under a light microscope (Leica DM LB2; 
Leica Microsystems, Wetzlar, Germany). Necrosis and 
fibrosis were blindly evaluated by a trained pathologist. 
Necrosis was scored using the following criteria: grade 
0, normal histology; grade 1, characterized by sin-
gle-cell necrosis to centrilobular necrosis limited to the 
area immediately around the centrilobular vein; grade 
2, characterized by centrilobular necrosis with frequent 
central to central bridging necrosis; grade 3, character-
ized by centrilobular necrosis affecting the hepatocytes 
in the centrilobular zone and multifocally extending 
to the midzonal hepatocytes, with central to central 
bridging; congestion and hemorrhage are common; 
grade 4, characterized by confluent necrosis involving 
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several entire adjacent lobules and widespread areas of 
congestion and hemorrhage in the centrilobular and 
midzonal areas of the liver.
triglyCeriDe QuantiFiCation
Neutral lipids were extracted from 50 mg of liver 
by homogenization in a 2:1 mixture of chloroform:-
methanol and overnight incubation. After 15 minutes 
centrifugation at 800g, the supernatant containing the 
lipid fraction was transferred to a clean glass vial and 
one fifth of 0.9% NaCl was added. For triglyceride 
quantification, the glycerol phosphate oxidase–peroxi-
dase enzymatic colorimetric assay (Triglycerides GPO-
POD kit; Spinreact, Girona, Spain) was used, following 
the manufacturer’s specifications.
statistiCal analysis
GraphPad Prism6 software (GraphPad Software, La 
Jolla, CA) was used for statistical analysis. According 
to the nature of the data, one-way analysis of variance 
Fig. 1. Resolution of necrosis after induction of acute liver injury is delayed in CD26KO mice compared to C57BL/6 controls. (A) 
Acute liver injury was induced in 10-week-old C57BL/6 (B6) and CD26KO male mice by a single intraperitoneal injection of 300 mg/kg 
APAP, and livers were analyzed at 24 hours and 72 hours postinjection. (B) Necrotic lesions (n; delineated by a dotted line) were examined 
in liver histologic sections and (C) scored from 0 to 4 according to location and extension. (D,E) The proportion of recruited CD45+ 
hematopoietic cells and Kupffer cells (F480highMac1+Ly6c-CD45+ cells) determined by flow cytometry is represented. (F) DPP-4 
activity in serum of B6 control (PBS-treated) and APAP-treated mice is depicted in arbitrary units, representing the rate of substrate 
decay during the enzymatic assay normalized to the average value of the controls. Scale bar,100 µm. Horizontal bars indicate mean values. 
*P < 0.05, **P < 0.01, and ***P < 0.001 in one-way analysis of variance using Tukey’s correction. Plots depict cumulative data from three 
independent experiments, n = 4-6 mice/group. Abbreviations: A.U., arbitrary unit; Ctrl, control; i.p., intraperitoneal; o.n., overnight.
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with Tukey’s correction or unpaired Student t tests 
were applied, as specified in each figure legend. P values 
are reported for two-tailed tests with a 95% confidence 
interval, and differences with P < 0.05 were considered 
significant.
Results
CD26Ko miCe sHoW DelayeD 
tissue reCoVery FolloWing 
aCute liVer inJury
To ascertain the impact of liver inflammation on 
liver macrophage populations and CD26/DPP-4 
expression/activity, we used a mouse model of acute 
liver injury induced by APAP (Fig. 1A), which causes 
severe hepatic necrosis and innate immune activation 
with marked leukocyte infiltration into the liver.(23) A 
single injection with 300 mg/kg of APAP caused exten-
sive hepatotoxicity at 24 hours as evidenced by serum 
markers of liver damage (aspartate aminotransferase 
and alanine aminotransferase) in both C57BL/6 and 
CD26KO mice (Supporting Fig. S1A,B). At 24 hours, 
both strains showed extensive centrilobular necrosis 
that, at 72 hours, was markedly recovered in C57BL/6 
mice but was still severe in 40% of CD26KO mice (Fig. 
1B,C). Likewise, significant recruitment of hematopoi-
etic-derived leukocytes (CD45+) was noticeable at 24 
Fig. 2. Serum CD26/DPP-4 activity, hematopoietic cell populations, and surface expression of CD26/DPP-4 during acute liver injury. 
(A) DPP-4 activity in the serum of C57BL/6 control (PBS-treated) and APAP-treated mice analyzed at 24 hours and 72 hours (depicted 
in arbitrary units, representing the rate of substrate decay during the enzymatic assay normalized to the average value of the controls; 
right axis, filled triangles linked by dashed line) was superimposed on (B) the proportion of Kupffer cells (F480highMac1+Ly6c-
CD45+ cells), (C) the proportion of CD45+ cells in the liver, and (D) the proportion of blood monocytes (Ly6c+ among CD45+ cells) 
as well as (E) the median f luorescent intensity of CD26/DPP-4 on Kupffer cells, (F) on liver CD45+ cells, and (G) on blood monocytes 
(left axis, empty squares linked by straight line). Mean values and SDs are represented; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001 in one-way analysis of variance using Tukey’s correction. Plots represent one of three independent experiments, n = 3-4 mice/
group. Abbreviations: A.U., arbitrary units; MFI, mean f luorescent intensity.
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hours in both strains, while at 72 hours, it only remained 
significantly increased in CD26KO mice (Fig. 1D; 
Supporting Fig. S2). On the other hand, reduction in 
KC populations was observed at 24 hours postinjection 
and was sustained at 72 hours in both C57BL/6 and 
CD26KO mice (Fig. 1E; Supporting Figs. S3 and S4).
Interestingly, APAP caused a significant increase in 
serum CD26/DPP-4 activity observed at 24 hours and 
72 hours in C57BL/6 mice (Fig. 1F; Fig. 2A). We super-
imposed the profiles of serum CD26/DPP-4 activity 
with the variation of KCs, liver-recruited hematopoi-
etic cells (CD45+), and Ly6c+ peripheral blood mono-
cyte populations (Fig. 2). While the proportion of KCs 
showed inverse dynamics relative to serum enzymatic 
levels, decreasing as enzymatic activity increased, the 
proportion of recruited hematopoietic cells observed 
both in the liver and in circulation increased at 24 hours 
but showed a faster reduction at 72 hours when com-
pared to the enzymatic activity (Fig. 2B-D). When mea-
suring CD26/DPP-4 surface expression in KCs and 
Fig. 3. Pharmacologic inhibition of CD26/DPP-4 enzymatic activity during acute liver injury leads to delayed resolution of necrosis. 
(A) Sitagliptin (100 mg/kg; Sita+APAP group) or water (APAP group) was administered by daily gavage to 10-week-old C57BL/6 (B6) 
mice before and after APAP intraperitoneal injection. Control B6 mice received water gavage and PBS injections. Livers were analyzed 
72 hours after APAP injection and compared with controls. (B) Necrotic lesions (n; delineated by dotted line) were examined in liver 
histologic sections and (C) scored from 0 to 4 according to location and extension. The proportion of recruited (D) hematopoietic 
CD45+ cells and (E) KCs (F480highMac1+Ly6c-CD45+ cells) was determined by f low cytometry. Scale bar, 100 µm. Horizontal 
bars indicate mean values; *P < 0.05, **P < 0.01, and ***P < 0.001 in one-way analysis of variance using Tukey’s correction. Plots 
depict cumulative data from two independent experiments, n = 6-9 per group. Abbreviations: A.U., arbitrary unit; Ctrl, control; i.p., 
intraperitoneal; Sita, sitagliptin. 
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liver-recruited hematopoietic cells (CD45+), we found 
a significant down-regulation of CD26/DPP-4 surface 
expression at 24 hours but not at 72 hours (Fig. 2E,F). 
The same tendency was observed in Ly6c+ circulating 
monocytes, although the level of CD26/DPP-4 expres-
sion on these cells was remarkably lower compared to 
the liver populations (Fig. 2G). Thus, in this context, the 
loss of CD26/DPP-4 expression is not cell-type spe-
cific. These results suggest that fluctuations in recruited 
hematopoietic cells may be related to the rise in serum 
CD26/DPP-4 activity during the inflammatory period 
but not with its persistence at 72 hours after injury. 
However, it did not escape our attention that both the 
decrease in the KC population and the elevation of CD26/
DPP-4 serum activity levels were sustained during the 
recovery phase (72 hours). Given that CD26KO mice 
showed an impaired recovery response, these observa-
tions suggest that the contribution of CD26/DPP-4 to 
Fig. 4. Alterations in Kupffer cell populations and changes in serum CD26/DPP-4 activity after chronic liver injury. (A,B) Chronic 
liver injury was induced by CCl4 in C57BL/6, leading to evident inf lammation and fibrosis at 24 hours and fibrosis regression and 
fibrosis resolution by 72 hours and 144 hours, respectively. (C) Serum CD26/DPP-4 enzymatic activity was determined at 24 hours, 
72 hours, and 144 hours after treatment and superimposed on (D) the proportion of KCs and (E) the proportion of liver Ly6c+ cells at 
the same time points. Arbitrary units represent the rate of substrate decay during the enzymatic assay normalized to the average value 
of the controls. Necrotic lesions are identified by "n" and delineated by a dotted line. Scale bar, 100 µm. Mean values are depicted, and 
error bars indicate SD. *P < 0.05 in unpaired t test. Plots depict cumulative data from a minimum of three independent experiments, n 
= 6-8 mice per group. Abbreviations: A.U., arbitrary units; H&E, hematoxylin and eosin; inf lam, inf lammation; i.p., intraperitoneal; 
Reg, regression; Resol, resolution; v, volume.
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tissue recovery response is related to the increased secre-
tion of the CD26/DPP-4 soluble form.
inHiBition oF CD26/Dpp-4 
enZymatiC aCtiVity leaDs 
to DelayeD reCoVery From 
neCrosis FolloWing aCute 
liVer inJury
To determine the role of DPP-4 enzymatic activ-
ity in the recovery of APAP-induced liver injury, we 
made use of sitagliptin, a clinically approved DPP-4 
inhibitor (Fig. 3A). At 24 hours after APAP injection, 
we observed extensive necrosis and hematopoietic cell 
recruitment (Supporting Figs. S2 and S5) accompa-
nied by elevation of serum markers of liver damage 
(aspartate aminotransferase and alanine aminotrans-
ferase) (Supporting Fig. S1C,D), irrespective of sita-
gliptin treatment. However, at 72 hours after APAP 
injection, the sitagliptin-treated C57BL/6 mice pre-
sented a higher proportion of hematopoietic-recruited 
cells in the liver and a more severe necrosis score when 
compared to untreated mice (Fig. 3B-D; Supporting 
Fig. S2). The reduction in KCs was similar in treated 
and nontreated mice submitted to APAP (Fig. 3E; 
Supporting Fig. S4). Thus, pharmacologic inhibition 
of CD26/DPP-4 enzymatic activity during acute liver 
injury was able to reproduce the delayed recovery from 
necrosis observed in APAP-treated CD26KO mice. 
These results reinforce the notion that CD26/DPP-4 
enzymatic activity contributes to the resolution of 
hepatocyte necrosis during recovery.
CD26/Dpp-4 enZymatiC 
aCtiVity inCreases During 
CHroniC liVer Damage 
Correlating WitH sHiFts in 
tHe KC population
To assess whether CD26/DPP-4 serum activity 
was also implicated in chronic liver damage, we used 
a mouse model of repeated exposure to CCl4. In this 
model, CCl4 is administered twice a week for 4 weeks to 
induce chronic hepatotoxicity. Development and regres-
sion of tissue damage and mild fibrosis were evaluated 
at 24 hours, 72 hours, and 144 hours after treatment 
(Fig. 4A). As expected,(24) necrosis and fiber deposi-
tion as well as up-regulation of inflammation-related 
genes were marked features of pathology at 24 hours 
after treatment (Fig. 4B; data not shown). At 72 hours, 
necrosis and fibrosis started to regress and by 144 hours 
were nearly resolved (Fig. 4B). Dramatic changes in the 
phenotype of liver macrophage populations accompa-
nied this process. In particular, we observed a remark-
able decrease in the KC population at 24 hours during 
the inflammatory/fibrotic period when the proportion 
of Ly6c+ recruited cells is higher and its recovery at 72 
hours when fibrosis retrogression occurs (Fig. 4D,E).
Interestingly, serum CD26/DPP-4 enzymatic activ-
ity significantly increased when the KC population was 
lowest but decreased when macrophages with the KC 
phenotype re-emerged (Fig. 4C,D). As in the acute liver 
injury model, the rise in Ly6c+ recruited cells at 24 hours 
paralleled the increase in CD26/DPP-4 enzymatic activ-
ity, but this correlation was lost at later time points (Fig. 
4D,E). These data revealed that the kinetics of serum 
CD26/DPP-4 activity may be a surrogate systemic 
marker for the dynamic shifts observed in KC popula-
tions in the context of acute and chronic liver damage.
liVer maCropHage 
populations anD serum CD26/
Dpp-4 enZymatiC aCtiVity 
are unCHangeD in initial 
DysmetaBoliC stages
We further analyzed a mouse model of the initial 
stages of nonalcoholic fatty liver disease induced by short-
time exposure to an HCD, representing mild hepatocyte 
dysfunction (Fig. 5). We observed that the levels of tri-
glycerides in the serum and liver as well as body weight 
gain were significantly increased in C57BL/6 mice after 
6 weeks of the HCD (Fig. 5A-C); however, no change 
in overall CD26/DPP-4 enzymatic levels was detected 
in serum (Fig. 5D). Notably, this short HCD regimen 
was not associated with significant alterations of KC 
populations or recruitment of bone marrow-derived 
inflammatory cells (Fig. 5E-H). Interestingly, a decrease 
in the intensity of CD26/DPP-4 expression on KCs 
was observed to occur with the HCD (Fig. 5I,J).
Depletion oF KCs leaDs 
to marKeD inCrease in 
serum leVels oF CD26/Dpp-4 
enZymatiC aCtiVity
We further tested the hypothesis that KC deple-
tion in the absence of hepatocyte damage and marked 
Hepatology CommuniCations, Vol. 2, no. 9, 2018 Duarte et al.
1089
Fig. 5. A hypercaloric diet induces CD26/DPP-4 down-modulation in Kupffer cells but does not alter serum CD26/DPP-4 enzymatic 
activity. Triglycerides were quantified in the (A) serum and (B) liver of C57BL/6 (B6) mice exposed to 6 weeks of standard chow or 
an HCD. (C) Body weight gain and (D) serum CD26/DPP-4 enzymatic activity (depicted in arbitrary units, representing the rate 
of substrate decay during the enzymatic assay) were quantified. (E) Flow cytometry plots illustrate the gating strategy for analysis 
of recruited bone marrow-derived cells (Ly6c+) and Kupffer cells (F4/80+ cells among Ly6c–). (F) The proportion of cells within 
macrophage morphological gate, (G) proportion of Ly6c+ cells within this gate, and (H) proportion of Kupffer cells are represented for 
B6 on standard chow or HCD. (I) Flow cytometry plots identifying a CD26 high population among Kupffer cells in B6 mice fed with 
standard chow or HCD. (J) Median expression of CD26 in CD26+ Kupffer cells. Plots depict cumulative data from two independent 
experiments, n = 7-8 mice/group; *P < 0.05, ****P < 0.0001 in unpaired t tests. Abbreviation: TG, triglyceride. 
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inflammatory reaction leads to increased levels of 
serum CD26/DPP-4 enzymatic activity. Intravenous 
injection of liposomes containing clodronate is widely 
used as a noninflammatory method to deplete phago-
cytic macrophages, being particularly efficient at tar-
geting the KC compartment(25) (Supporting Fig. S6). 
We analyzed livers harvested at 2, 7, 14, and 30 days 
postinjection (Fig. 6A). KC depletion did not appear 
to induce significant changes in the Ly6c+ macrophage 
cell population, indicating that no major bone marrow 
monocyte recruitment was occurring (Fig. 6B-D). As 
expected, the KC population was undetectable at day 2 
postinjection and gradually recovered from day 7 to day 
30 (Fig. 6E). Remarkably, serum CD26/DPP-4 enzy-
matic activity increased significantly with KC deple-
tion and re-establishment of CD26/DPP-4 basal levels 
followed the kinetics of KC replenishment (Fig. 6E,F). 
These results strongly suggest that, irrespective of pat-
ent parenchymal damage or significant recruitment of 
circulating hematopoietic cells, induction of dramatic 
perturbations in KC populations correlates with inverse 
alterations of serum CD26/DPP-4 activity.
Fig. 6. Depletion of Kupffer cells with clodronate liposomes induces an increase in serum CD26/DPP-4 enzymatic levels. (A) Groups 
of three C57BL/6 males were injected with liposomes containing clodronate (5 g/mL) or PBS and analyzed at 2, 7, 14, and 30 days 
postinjection. The proportion of LY6C+ monocyte/macrophage cells in the liver at (B) day 2, (C) day 7, and (D) day 14 is represented. 
(E,F) The proportion of Kupffer cells is superimposed on the levels of serum CD26/DPP-4 activity measured in treated mice and 
compared to untreated control mice at the same time points. Arbitrary units represent the rate of substrate decay during the enzymatic 
assay normalized to the average value of the controls. Scale bar, 100 µm. Mean values and error bars indicating SD are represented. *P 
< 0.05, **P < 0.01, and ***P < 0.001 in one-way analysis of variance using Tukey’s multiple comparison test. Data are representative of 
two independent experiments, n = 3-4 mice/group. Abbreviations: A.U., arbitrary units; i.v., intravenous.
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CD26/Dpp-4 is not reQuireD 
For KC aCtiVation But 
is seCreteD FolloWing 
proinFlammatory 
stimulation
To study the contribution of CD26/DPP-4 to 
KC activation, we exposed sort-purified KCs from 
C57BL/6 and CD26KO mice to LPS for 24 hours 
(Fig. 7). Secretion of TNF-α and IL-6 proinflamma-
tory cytokines was similar in B6 and CD26KO KCs 
exposed to LPS (Fig. 7A,B). Likewise, treatment 
with sitagliptin, a specific DPP-4 inhibitor that com-
pletely abrogated the CD26/DPP-4 activity, did not 
impair induction of TNF-α and IL-6 secretion by KCs 
in response to LPS (Fig. 7C-E). This suggests that 
CD26/DPP-4 is not required for KC proinflammatory 
Fig. 7. Genetic ablation or pharmacologic inhibition of CD26/DPP-4 enzymatic activity does not prevent Kupffer cell activation in 
vitro. (A) TNF-α secretion and (B) IL-6 were measured by enzyme-linked immunosorbent assay in the supernatant of sort-purified 
Kupffer cells isolated from C57BL/6 (B6) and CD26KO mice, either unstimulated or stimulated in vitro with 1 µg/mL LPS. (C) 
CD26/DPP-4 enzymatic activity, (D) TNF-α, and (E) IL-6 secretion by Kupffer cells from B6 mice were also measured in the 
presence or absence of 10 µM or 100 µM of the DPP-4 inhibitor sitagliptin with or without LPS stimulation (1 µg/mL, 24 hours). 
(F) Sort-purified Kupffer cells were incubated for 24 hours with clodronate-containing liposomes (5 g/mL) diluted 1/10 or 1/100 in 
cell culture medium; cell viability was assessed using the MTT assay, and (G) CD26/DPP-4 enzymatic activity in the supernatant 
was quantified. Arbitrary units represent the rate of substrate decay during the enzymatic assay either normalized (G) or not (C) to 
the average value of the controls. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 in one-way analysis of variance with Tukey’s 
correction. Data are representative of at least two independent experiments. Abbreviations: A.U., arbitrary units; lips-Clod, liposome-
clodronate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sita, sitagliptin; Unst, unstimulated.
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activation. Nevertheless, CD26/DPP-4 enzymatic 
activity increased in the supernatant of LPS-stimulated 
cultures (Fig. 7C). Furthermore, we observed that CD26/
DPP-4 activity in KC supernatants was decreased when 
KCs undergo cell death following exposure to lipo-
somes containing clodronate (Fig. 7F,G). These results 
indicate that an increase in CD26/DPP-4 release is an 
active response of KCs undergoing activation that could 
be involved in local liver repairing responses.
Discussion
This work revealed that CD26/DPP-4 enzymatic 
activity exerts unexpected beneficial effects in the 
recovery response to hepatocyte damage. We found 
that the influx of infiltrating hematopoietic CD45+ 
cells and the necrosis response at initial stages of 
APAP-induced hepatotoxic damage (24 hours) were 
not affected by CD26 genetic ablation or pharma-
cologic inhibition of CD26/DPP-4. However, at the 
recovery time point (72 hours), the proportion of infil-
trating CD45+ cells was still significantly increased 
and noticeable necrosis persisted when CD26/DPP-4 
enzymatic ability was disabled. These findings support 
the hypothesis that CD26/DPP-4 enzymatic activity 
plays a role in controlling leukocyte infiltration in the 
damaged liver and in resolving hepatic necrosis during 
recovery from acute liver injury.
In addition, we observed that extensive shifts in 
liver macrophage populations, consequent to acute and 
chronic liver injury, entail marked reductions in the typ-
ical KC population that are associated with increased 
CD26/DPP-4 enzymatic activity in the serum. 
Interestingly, depletion of KCs induced by clodro-
nate-loaded liposomes also correlated with increased 
serum CD26/DPP-4 enzymatic activity, suggesting 
that the critical triggering factor is the reduction of 
KCs in the liver and not the inflammatory response 
related to tissue damage. Accordingly, short exposure 
to an HCD that failed to induce perturbations in the 
KC proportions also showed unaltered serum CD26/
DPP-4 enzymatic levels, despite inducing increased 
triglyceride production and weight gain. These results 
suggest that in the absence of major perturbations in 
the KC population, metabolic changes in hepatocytes 
are not sufficient to augment the CD26/DPP-4 enzy-
matic activity in the serum.
CD26/DPP-4 acts as a posttranslational modifier 
of certain chemokines(26) and thereby could mediate 
or facilitate the migration/expansion of cells involved 
in faster clearance of the inflamed microenvironment, 
controlling the recovery dynamics of cell population 
niches, namely KCs. It is remarkable that the time 
course correlation of CD26/DPP-4 serum activity and 
KC depletion/recovery was similar in the CCl4 chronic 
liver model and in the model of clodronate-induced 
depletion. This indicates that during the response to 
liver damage significant alterations in the levels of cir-
culating CD26/DPP-4 are mirroring KC reduction/
recovery phases and represent a quantitative marker 
of major perturbations in this cell compartment. 
Interestingly, these results are in accordance with pre-
vious observations reporting increases in DPP-4 enzy-
matic levels in patients with severe liver pathology.(8,16)
The cellular contribution to increased serum CD26/
DPP-4 enzymatic activity that we observed in mod-
els of perturbed liver homeostasis remains unclear. 
We have noted a reduction of CD26/DPP-4 surface 
expression in KCs under exposure to an HCD and in 
hematopoietic cells in mice receiving APAP treatment 
that did not correlate with the dynamics of CD26/
DPP-4 serum activity. Thus, down-modulation of 
CD26/DPP-4 expression appears to be functionally 
related to cell activation but not with the increased 
levels of CD26/DPP-4 in the serum. CD26/DPP-4 
could be released by KCs undergoing depletion; how-
ever, we found that in vitro induction of KC death 
does not lead to CD26/DPP-4 release. Nevertheless, 
these findings raise the possibility that local CD26/
DPP-4 release by activated KCs could promote tissue 
repair responses that are impaired in CD26KO mice. 
On the other hand, vascular endothelial cells and to 
some extent bone marrow-derived hematopoietic cells 
have been shown to contribute to steady-state serum 
DPP-4 levels.(11) Recruited hematopoietic cells could 
contribute to serum CD26/DPP-4 activity during the 
acute inflammatory phase of disease, but the serum 
enzymatic activity remained elevated during recovery 
periods when hematopoietic recruitment in the liver 
damage models was already significantly reduced. 
Furthermore, hematopoietic cell recruitment does not 
explain the alterations in serum CD26/DPP-4 activity 
in the noninflammatory model of KC depletion by clo-
dronate liposome injection.
In the liver, KCs are in close contact with liver 
sinusoidal endothelial cells.(27) Genetic ablation of 
DPP-4 expression on vascular endothelial cells caused 
down-regulation of CD26/DPP-4 gene expression 
and reduction of DPP-4 activity in liver tissue and in 
serum; this provides a link between liver endothelial 
cells and peripheral DPP-4 activity.(11) It is possible 
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that significant shifts in resident KC populations are 
perceived as signals for other liver NPC activation, 
leaving open the possibility that endothelial cells 
respond by releasing soluble CD26/DPP-4 into circu-
lation or propagating the signaling leading to vascular 
release of the enzyme.
Our results in mouse models of induced acute hepato-
toxicity suggest that CD26/DPP-4 inhibition therapies 
may be detrimental in patients with acute liver damage. 
Nevertheless, CD26/DPP-4 inhibition in experimental 
models of fibrosis development appears to be benefi-
cial.(20,21,28) Pharmacologic inhibition of CD26/DPP-4 
in rats was shown to prevent porcine serum-induced 
fibrosis due to attenuation of hepatic stellate cell acti-
vation.(20) In addition, it was reported that CD26KO 
mice are protected from CCL4-induced chronic fibrosis, 
showing decreased inflammation and recruitment of B 
lymphocytes and reduced alterations in energy metab-
olism.(21) Together, these observations concur with the 
possibility that CD26/DPP-4 plays a dual role in acute 
liver damage and in fibrosis response. Recently, expres-
sion of CD26/DPP-4 was identified as a marker of cell 
senescence and a contributor to the development of this 
cellular program.(29) Interestingly, senescence was shown 
to be required for swift wound healing after liver injury 
in young organisms but highly unfavorable when there 
is persistence of the insult, as observed in severe chronic 
liver disease.(30) Given that CD26/DPP-4 is multi-
functional and ubiquitous, it is plausible that the liver 
microenvironment and inflammatory context govern the 
outcomes of CD26/DPP-4 action.
In summary, we uncovered a novel role for CD26/
DPP-4 activity during liver pathology. We found that 
CD26/DPP-4 enzymatic activity licenses the swift 
resolution of drug-induced liver necrosis in acute liver 
damage. Furthermore, we unveiled that drastic changes 
in KC populations lead to alterations in serum CD26/
DPP-4 activity that holds potential value as a bio-
marker and quantitative sensor of the KC niche during 
clinical and subclinical liver conditions.
Acknowledgment: The authors acknowledge the histol-
ogy and the flow cytometry units at Instituto Gulbenkian 
de Ciência, in particular Dr. Rui Pedro Faísca and 
Cláudia Bispo for excellent technical assistance.
reFerenCes
 1) De Meester I, Korom S, Van Damme J, Scharpé 
S. CD26, let it cut or cut it down. Immunol Today 
1999;20:367-375.
 2) Hopsu-Havu VK, Glenner GG. A new dipeptide naph-
thylamidase hydrolyzing glycyl-prolyl-beta-naphthylam-
ide. Histochemie 1966;7:197-201.
 3) Drucker DJ, Nauck MA. The incretin system: glu-
cagon-like peptide-1 receptor agonists and dipepti-
dyl peptidase-4 inhibitors in type 2 diabetes. Lancet 
2006;368:1696-1705.
 4) Barreira da Silva R, Laird ME, Yatim N, Fiette L, 
Ingersoll MA, Albert ML. Dipeptidylpeptidase 4 inhi-
bition enhances lymphocyte trafficking, improving both 
naturally occurring tumor immunity and immunother-
apy. Nat Immunol 2015;16:850-858.
 5) Klemann C, Wagner l, Stephan M, von Hörsten S.  
Cut to the chase: a review of CD26/dipeptidyl pepti-
dase-4’s (DPP4) entanglement in the immune system. 
Clin Exp Immunol 2016;185:1-21.
 6) Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. 
Front Immunol 2015;6:386.
 7) Kim N-H, Yu T, Lee DH. The nonglycemic actions 
of dipeptidyl peptidase-4 inhibitors. Biomed Res Int 
2014;2014:368703.
 8) Cordero OJ, Salgado FJ, Nogueira M. On the origin of 
serum CD26 and its altered concentration in cancer pa-
tients. CancerImmunol Immunother 2009;58:1723-1747.
 9) Ansorge S, Nordhoff K, Bank U, Heimburg A, Julius H, 
Breyer D, et al. Novel aspects of cellular action of dipep-
tidyl peptidase IV/CD26. Biol Chem 2011;392:153-168.
 10) Röhrborn D, Eckel J, Sell H. Shedding of dipeptidyl 
peptidase 4 is mediated by metalloproteases and up-regu-
lated by hypoxia in human adipocytes and smooth muscle 
cells. FEBS Lett 2014;588:3870-3877.
 11) mulvihill ee, Varin em, Gladanac B, Campbell JE, 
Ussher JR, Baggio LL, et al. Cellular sites and mech-
anisms linking reduction of dipeptidyl peptidase-4 ac-
tivity to control of incretin hormone action and glucose 
homeostasis. CellMetab 2017;25:152-165.
 12) Baumeier C, saussenthaler s, Kammel A, Jähnert M, 
Schlüter L, Hesse D, et al. Hepatic DPP4 DNA methyl-
ation associates with fatty liver. Diabetes 2017;66:25-35.
 13) Fukui Y, Yamamoto A, Kyoden T, Kato K, Tashiro Y. 
Quantitative immunogold localization of dipeptidyl pep-
tidase IV (DPP IV) in rat liver cells. CellStruct Funct 
1990;15:117-125.
 14) Ju C, Tacke F. Hepatic macrophages in homeostasis and 
liver diseases: from pathogenesis to novel therapeutic 
strategies. Cell Mol Immunol 2016;13:316-327.
 15) Duarte N, Coelho IC, Patarrão RS, Almeida JI, Penha-
Gonçalves C, Macedo MP. How inflammation impinges 
on NAFLD: a role for Kupffer cells. Biomed Res Int 
2015;2015:984578.
 16) Bae EJ. DPP-4 inhibitors in diabetic complications: 
role of DPP-4 beyond glucose control. Arch Pharm 
Res 2016;39:1114-1128. Erratum. In: Arch Pharm Res 
2016;39:1335.
 17) Smits MM, Tonneijck L, Muskiet MH, Kramer MH, 
Pouwels PJ, Pieters-van den Bos IC, et al. Twelve week 
liraglutide or sitagliptin does not affect hepatic fat in 
type 2 diabetes: a randomised placebo-controlled trial. 
Diabetologia 2016;59:2588-2593.
 18) Cui J, Philo L, Nguyen P, Hofflich H, Hernandez 
C, Bettencourt R, et al. Sitagliptin vs. placebo for 
Duarte et al. Hepatology CommuniCations, september 2018
1094
non-alcoholic fatty liver disease: a randomized controlled 
trial. J Hepatol 2016;65:369-376.
 19) Tilg H, Moschen AR, Roden M. NAFLD and diabetes 
mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32-42.
 20) Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, 
Douhara A, et al. Dipeptidyl peptidase-4 inhibitor atten-
uates hepatic fibrosis via suppression of activated hepatic 
stellate cell in rats. J Gastroenterol 2014;49:481-491.
 21) Wang XM, Holz LE, Chowdhury S, Cordoba SP, Evans 
KA, Gall MG, et al. The pro-fibrotic role of dipeptidyl 
peptidase 4 in carbon tetrachloride-induced experimen-
tal liver injury. Immunol Cell Biol 2017;95:443-453.
 22) Gonçalves LA, Rodo J, Rodrigues-Duarte L, de Moraes 
LV, Penha-gonçalves C. HGF secreted by activated 
Kupffer cells induces apoptosis of plasmodium-infected 
hepatocytes. Front Immunol 2017;8:90.
 23) Zigmond e, samia-grinberg s, Pasmanik-Chor M, 
Brazowski E, Shibolet O, Halpern Z, et al. Infiltrating 
monocyte-derived macrophages and resident kupffer 
cells display different ontogeny and functions in acute 
liver injury. J Immunol 2014;193:344-353.
 24) Ramachandran P, Pellicoro A, Vernon M a, Boulter L, 
Aucott RL, Ali A, et al. Differential Ly-6C expression 
identifies the recruited macrophage phenotype, which 
orchestrates the regression of murine liver fibrosis. Proc 
Natl Acad Sci U S A 2012;109:E3186-E195.
 25) Van Rooijen N, Sanders A. Kupffer cell depletion by 
liposome-delivered drugs: comparative activity of in-
tracellular clodronate, propamidine, and ethylenedi-
aminetetraacetic acid. Hepatology 1996;23:1239-1243.
 26) Mortier A, Gouwy M, Van Damme J, Proost P, Struyf S. 
CD26/dipeptidylpeptidase IV-chemokine interactions: 
double-edged regulation of inf lammation and tumor bi-
ology. J Leukoc Biol 2016;99:955-969.
 27) Malarkey DE, Johnson K, Ryan L, Boorman G, 
Maronpot RR. New insights into functional as-
pects of liver morphology. Toxicol Pathol 2005;33: 
27-34.
 28) Abo-Haded HM, Elkablawy MA, Al-Johani Z, Al-
Ahmadi O, El-Agamy DS. Hepatoprotective effect of 
sitagliptin against methotrexate induced liver toxicity. 
PLoS One 2017;12:e0174295.
 29) Kim KM, Noh JH, Bodogai M, Martindale JL, Yang X, 
Indig FE, et al. Identification of senescent cell surface  
targetable protein DPP4. Genes Dev 2017;31:1529-1534.
 30) Aravinthan AD, Alexander GJM. Senescence in 
chronic liver disease: is the future in aging? J Hepatol 
2016;65:825-834.
Author names in bold designate shared co-first 
authorship.
Supporting Information
Additional Supporting Information may be found at 
onlinelibrary.wiley.com/doi/10.1002/hep4.1225/suppinfo.
